Markets

Brean Murray Starts Johnson & Johnson as a “Buy” (JNJ)

Healthcare products giant Johnson & Johnson ( JNJ ) on Wednesday saw its coverage initiated with a "Buy" rating by analysts at Brean Murray Carret & Co.

The firm also set a $77 price target on JNJ shares, suggesting a 15% upside to the stock's Tuesday closing price of $67.10.

A Brean Murray analyst commented, "After several years of subpar fundamentals and some unexpected headwinds, J&J appears poised for earnings reacceleration, due to a pipeline-driven revenue upswing in Pharma, stable MD&D trends, and trough for Consumer sales.

Johnson & Johnson shares fell 34 cents, or -0.5%, in premarket trading Wednesday.

The Bottom Line

We have been recommending Johnson & Johnson ( JNJ ) since Apr.29, 2011, when the stock was trading at $67.10. The company has a 3.40% dividend yield, based on last night's closing stock price of $67.10.

Johnson & Johnson ( JNJ ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.6 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Created by Dividend.com


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

Latest Markets Videos